tiprankstipranks
Xeris Biopharma enters collaboration, license agreement with Beta Bionics
PremiumThe FlyXeris Biopharma enters collaboration, license agreement with Beta Bionics
2M ago
Xeris Biopharma enters exclusive license agreement with Beta Bionics
PremiumThe Fly
Xeris Biopharma enters exclusive license agreement with Beta Bionics
2M ago
Xeris Biopharma initiated with an Outperform at Oppenheimer
PremiumThe Fly
Xeris Biopharma initiated with an Outperform at Oppenheimer
3M ago
Xeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
PremiumThe FlyXeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
4M ago
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
PremiumThe Fly
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
4M ago
Options Volatility and Implied Earnings Moves Today, March 06, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 06, 2024
4M ago
Xeris Biopharma price target lowered to $5.50 from $6 at H.C. Wainwright
PremiumThe FlyXeris Biopharma price target lowered to $5.50 from $6 at H.C. Wainwright
8M ago
Xeris Biopharma reports Q3 EPS (9c), consensus (12c)
PremiumThe Fly
Xeris Biopharma reports Q3 EPS (9c), consensus (12c)
8M ago
Xeris Biopharma  tightens FY23 revenue view to $155M-$165M from $145M-$165M
PremiumThe Fly
Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100